This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Hims & Hers Health, Inc. (HIMS) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Hims & Hers Health (HIMS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
HSIC Gears Up for Q1 Earnings: Here's What You Need to Know
by Zacks Equity Research
Henry Schein is expected to report impressive Q1 2025 sales in each of its business segment and a positive pace of recovery from the cyber incident.
Here's How Charles River is Placed Just Ahead of Q1 Earnings
by Zacks Equity Research
CRL's first-quarter 2025 performance is expected to have been hurt by a challenging biopharmaceutical environment.
GYN Surgical Division Likely to Drive Hologic's Q2 Earnings
by Zacks Equity Research
HOLX's second-quarter fiscal 2025 performance is likely to have benefited from expanding breast health offerings.
Hims & Hers Health, Inc. (HIMS) Stock Drops Despite Market Gains: Important Facts to Note
by Zacks Equity Research
In the closing of the recent trading day, Hims & Hers Health, Inc. (HIMS) stood at $28.10, denoting a -0.14% change from the preceding trading day.
EPD Growth in Emerging Market Supports Abbott Stock Amid Macro Woes
by Zacks Equity Research
Abbott's Diabetes Care business continues to benefit from the growing sales of its flagship, sensor-based continuous glucose monitoring system, FreeStyle Libre.
Is Most-Watched Stock Hims & Hers Health, Inc. (HIMS) Worth Betting on Now?
by Zacks Equity Research
Recently, Zacks.com users have been paying close attention to Hims & Hers Health (HIMS). This makes it worthwhile to examine what the stock has in store.
Zacks Industry Outlook Highlights Veeva Systems, Hims & Hers Health and Butterfly Network
by Zacks Equity Research
Veeva Systems, Hims & Hers Health and Butterfly Network are part of the Zacks Industry Outlook article.
Zimmer Biomet to Report Q1 Earnings: Here's What to Expect
by Zacks Equity Research
ZBH's Hips business is expected to have witnessed growth on the back of its suite of navigation solutions in direct anterior stems and surgical impactors.
Is it Apt to Retain Omnicell Stock in Your Portfolio Now?
by Zacks Equity Research
OMCL stays on investors' radar due to the strong performance of the SaaS and Expert Services portfolio.
Will Robust Exome and Genome Growth Boost WGS' Q1 Earnings Results?
by Zacks Equity Research
GeneDx is expected to have continued the strong 2024 momentum across all metrics in the first quarter of 2025.
Hims & Hers Health and AST SpaceMobile have been highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Hims & Hers Health and AST SpaceMobile are part of the Zacks Bull and Bear of the Day article.
IDXX Gears Up for Q1 Earnings: What to Expect From the Stock?
by Zacks Equity Research
IDEXX Laboratories' first-quarter 2025 performance is expected to have benefited from a strong execution against strategic priorities.
3 Medical Info Systems Stocks to Ride the AI Wave in Trump Tariff Era
by Urmimala Biswas
Zacks Medical Info Systems industry stocks like VEEV, HIMS and BFLY are expected to gain from the Stargate Project and provide relief amid tariff tension.
Bull of the Day: Hims & Hers Health (HIMS)
by Kevin Cook
Despite hiccups in GLP-1 market, HIMS estimates jump to +58% sales and +167% profits
Hims & Hers Health, Inc. (HIMS) Surpasses Market Returns: Some Facts Worth Knowing
by Zacks Equity Research
In the closing of the recent trading day, Hims & Hers Health, Inc. (HIMS) stood at $27.23, denoting a +1.04% change from the preceding trading day.
3 Undervalued Medical Device Stocks to Buy in 2025 Amid Tariff Woes
by Harshit Gupta
Here, we discuss three medical device stocks ,COR, HIMS and PBH, that offer cheap valuations, making them attractive bets amid tariff risks.
Should You Continue to Hold Veracyte Stock in Your Portfolio?
by Zacks Equity Research
Strength in the Afirma and Decipher franchises continues to bode well for VCYT stock.
Reasons to Hold TNDM Stock in Your Portfolio for Now
by Zacks Equity Research
A robust diabetes market and international expansion raise investors' optimism for Tandem Diabetes.
ALGN Gears Up for Q1 Earnings: What Lies Ahead for the Stock?
by Zacks Equity Research
Align Technology's first-quarter 2025 results are likely to reflect the strength in its Clear Aligner business.
Solid TMTT Growth to Drive Edwards Lifesciences' Q1 Earnings
by Zacks Equity Research
EW's first-quarter 2025 performance is likely to have gained from growth drivers across its businesses amid macroeconomic headwinds.
Will a Strong MA Business Aid Elevance Health's Q1 Earnings?
by Zacks Equity Research
ELV's Q1 results are expected to reap the benefits of higher premiums from growing Medicare Advantage membership and acquisitions pursued within the Carelon unit.
Is it the Right Time to Hold STERIS Stock in Your Portfolio?
by Zacks Equity Research
STE stays on investors' radars due to the strength of its Healthcare arm and strong rebound potential in the AST segment.
Labcorp Q1 Earnings Preview: Diagnostics Arm Likely to Drive Growth
by Zacks Equity Research
LH's first-quarter 2025 performance is likely to have benefited from both its Dx and BLS businesses.
Hims & Hers Stock Gains 5.8% in 3 Months: Here's How to Play it
by Debanjana Dey
HIMS is enhancing offerings and expanding its health and wellness products and services to solidify its footing. However, macro challenges are likely to hurt its performance.